Shenzhen New Industries Biomedical Engineering Co., Ltd.
SZSE:300832.SZ
60.24 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 3,914.402 | 3,046.956 | 2,545.415 | 2,194.967 | 1,681.588 | 1,383.611 | 1,140.565 | 922.505 | 731.682 | 545.276 | 378.123 | 258.082 |
| Cost of Revenue
| 1,170.268 | 906.203 | 734.303 | 500.869 | 337.003 | 265.477 | 243.273 | 195.542 | 178.087 | 130.755 | 104.913 | 84.71 |
| Gross Profit
| 2,744.134 | 2,140.753 | 1,811.112 | 1,694.098 | 1,344.585 | 1,118.134 | 897.292 | 726.963 | 553.596 | 414.522 | 273.21 | 173.373 |
| Gross Profit Ratio
| 0.701 | 0.703 | 0.712 | 0.772 | 0.8 | 0.808 | 0.787 | 0.788 | 0.757 | 0.76 | 0.723 | 0.672 |
| Reseach & Development Expenses
| 335.68 | 317.71 | 215.045 | 150.584 | 119.59 | 84.242 | 57.154 | 47.171 | 28.051 | 22.014 | 0 | 0 |
| General & Administrative Expenses
| 49.926 | 37.481 | 29.839 | 27.425 | 23.032 | 13.522 | 11.282 | 8.865 | 118.662 | 40.161 | 33.545 | 30.892 |
| Selling & Marketing Expenses
| 630.311 | 458.785 | 369.955 | 297.115 | 328.238 | 255.135 | 203.099 | 162.679 | 124.386 | 93.696 | 73.963 | 54.919 |
| SG&A
| 670.34 | 496.267 | 399.794 | 324.54 | 351.27 | 268.657 | 214.381 | 171.544 | 243.047 | 133.857 | 107.509 | 85.811 |
| Other Expenses
| -2.122 | -41.388 | 109.096 | 144.448 | 6.375 | -0.577 | -0.244 | 27.766 | 21.999 | 20.639 | 3.173 | 1.638 |
| Operating Expenses
| 1,006.019 | 772.589 | 723.935 | 619.571 | 477.235 | 348.974 | 267.049 | 243.779 | 293.025 | 136.939 | 110.52 | 87.455 |
| Operating Income
| 1,738.115 | 1,503.619 | 1,137.427 | 1,098.563 | 898.924 | 807.77 | 629.848 | 500.94 | 269.835 | 274.074 | 160.238 | 85.557 |
| Operating Income Ratio
| 0.444 | 0.493 | 0.447 | 0.5 | 0.535 | 0.584 | 0.552 | 0.543 | 0.369 | 0.503 | 0.424 | 0.332 |
| Total Other Income Expenses Net
| 154.95 | -2.417 | -1.898 | -1.801 | -0.459 | 38.032 | -0.639 | 45.253 | 30.608 | 19.198 | 2.06 | 1.277 |
| Income Before Tax
| 1,893.065 | 1,501.202 | 1,135.529 | 1,096.762 | 898.465 | 807.193 | 629.604 | 528.436 | 291.178 | 296.781 | 164.75 | 87.195 |
| Income Before Tax Ratio
| 0.484 | 0.493 | 0.446 | 0.5 | 0.534 | 0.583 | 0.552 | 0.573 | 0.398 | 0.544 | 0.436 | 0.338 |
| Income Tax Expense
| 239.412 | 173.283 | 161.833 | 157.615 | 125.856 | 113.196 | 91.397 | 76.742 | 42.06 | 43.908 | 23.482 | 12.079 |
| Net Income
| 1,653.653 | 1,327.918 | 973.696 | 939.147 | 772.609 | 693.997 | 538.207 | 451.695 | 249.119 | 252.872 | 141.268 | 75.129 |
| Net Income Ratio
| 0.422 | 0.436 | 0.383 | 0.428 | 0.459 | 0.502 | 0.472 | 0.49 | 0.34 | 0.464 | 0.374 | 0.291 |
| EPS
| 2.1 | 1.69 | 1.24 | 1.2 | 0.99 | 0.99 | 0.76 | 0.64 | 0.36 | 0.37 | 0.7 | 0.39 |
| EPS Diluted
| 2.1 | 1.69 | 1.24 | 1.2 | 0.99 | 0.99 | 0.76 | 0.64 | 0.36 | 0.37 | 0.7 | 0.39 |
| EBITDA
| 1,917.313 | 1,616.382 | 1,206.248 | 1,161.129 | 937.219 | 862.706 | 673.88 | 498.862 | 302.312 | 302.657 | 168.728 | 91.916 |
| EBITDA Ratio
| 0.49 | 0.53 | 0.474 | 0.529 | 0.557 | 0.624 | 0.591 | 0.541 | 0.413 | 0.555 | 0.446 | 0.356 |